# A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

> **NCT03535740** · PHASE2 · COMPLETED · sponsor: **Ariad Pharmaceuticals** · enrollment: 103 (actual)

## Conditions studied

- ALK-positive Advanced NSCLC

## Interventions

- **DRUG:** Brigatinib

## Key facts

- **NCT ID:** NCT03535740
- **Lead sponsor:** Ariad Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-31
- **Primary completion:** 2020-09-30
- **Final completion:** 2024-08-21
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2025-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03535740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03535740, "A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03535740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*